Italian pharmaceutical company, NTC, has granted licence and distribution rights of a portfolio of ophthalmic products to Mundipharma — a pharmaceutical company with a presence in ophthalmology.
Eye treatment
“Partnering selected ophthalmic products of our portfolio and pipeline with a leading company like Mundipharma is very valuable and important to NTC,” stated Riccardo Carbucicchio, president and CEO of NTC. “It also represents to us a confirmation about the value of the development efforts we are putting in the ophthalmic space.”
NTC’s portfolio of ophthalmic products address unmet medical needs in the treatment of several diseases, such as blepharitis, dry eye, allergy and glaucoma in the Middle East and Africa region.
“The NTC portfolio of products complements our current ophthalmology franchise very well and this deal marks an important step in our strategy to build a diversified portfolio and leverage on our strong market leadership in the Middle East & Africa Region,” commented Dr Ashraf Allam, vice president of Mundipharma Middle East, Turkey & Africa Region. “This is a great result for patients in the region, who will benefit from access to NTC’s products with higher therapeutic value.”
